CMR Surgical has raised $896M across 3 funding rounds. The latest round valued CMR Surgical at $3B post-money, with SoftBank on the lead line.
CMR Surgical raised $600 million at a $3 billion valuation in a 2021 Series D round led by Escala Capital and SoftBank Vision Fund 2, with GE Healthcare and ABB Technology Ventures also investing. It raised a further $165 million in September 2023 to launch its Versius soft tissue system into new markets.
3 funding rounds, the latest highlighted.
CMR Surgical was founded in 2014, United Kingdom.
Escala Capital was its biggest investor followed by SoftBank Vision Fund 2; other notable investors GE Healthcare and ABB Technology Ventures. $600M raised, led by Escala Capital, SoftBank Vision Fund 2.
A primary round — the company sells new shares to investors it selects. $165M raised.
A primary round — the company sells new shares to investors it selects. $131M raised, led by SoftBank.
No filing has been made.
3 dated rounds, newest first.
GE HealthcareAABB Technology VenturesThe last valuation is $3B (post-money, Apr 2025).
Lead investors for each round are in the funding timeline.
The closest medical devices & equipment (surgical robotics) peers are on the competitors page.
The routes section explains what is realistically available for a company at this stage.
No. CMR Surgical is a private company; its shares do not trade on a public exchange.
Perpetual markets for stocks, gold, indices and pre-IPO names — settled on-chain, no wallet-to-exchange transfers.
